JPWO2022195011A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022195011A5 JPWO2022195011A5 JP2023556906A JP2023556906A JPWO2022195011A5 JP WO2022195011 A5 JPWO2022195011 A5 JP WO2022195011A5 JP 2023556906 A JP2023556906 A JP 2023556906A JP 2023556906 A JP2023556906 A JP 2023556906A JP WO2022195011 A5 JPWO2022195011 A5 JP WO2022195011A5
- Authority
- JP
- Japan
- Prior art keywords
- pharma
- disorder
- acceptable salt
- ceutically acceptable
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims 22
- 150000001875 compounds Chemical class 0.000 claims 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 15
- SPCIYGNTAMCTRO-HXOHQZFQSA-N [2H]C([2H])([2H])N(C([2H])([2H])[2H])C([2H])([2H])C([2H])([2H])c1c[nH]c2cccc(O)c12 Chemical compound [2H]C([2H])([2H])N(C([2H])([2H])[2H])C([2H])([2H])C([2H])([2H])c1c[nH]c2cccc(O)c12 SPCIYGNTAMCTRO-HXOHQZFQSA-N 0.000 claims 11
- 208000035475 disorder Diseases 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 9
- 229910052805 deuterium Inorganic materials 0.000 claims 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 208000024714 major depressive disease Diseases 0.000 claims 6
- 238000000634 powder X-ray diffraction Methods 0.000 claims 6
- 239000012453 solvate Substances 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 4
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 4
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims 4
- 210000003169 central nervous system Anatomy 0.000 claims 4
- 208000029364 generalized anxiety disease Diseases 0.000 claims 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 4
- -1 hemifumarate Chemical compound 0.000 claims 3
- 239000002904 solvent Substances 0.000 claims 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- 201000001880 Sexual dysfunction Diseases 0.000 claims 2
- 206010041250 Social phobia Diseases 0.000 claims 2
- 206010065604 Suicidal behaviour Diseases 0.000 claims 2
- 206010042458 Suicidal ideation Diseases 0.000 claims 2
- 210000003403 autonomic nervous system Anatomy 0.000 claims 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims 2
- 150000001558 benzoic acid derivatives Chemical class 0.000 claims 2
- 208000018912 cluster headache syndrome Diseases 0.000 claims 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 2
- 229940076279 serotonin Drugs 0.000 claims 2
- 231100000872 sexual dysfunction Toxicity 0.000 claims 2
- 208000011117 substance-related disease Diseases 0.000 claims 2
- 150000003892 tartrate salts Chemical class 0.000 claims 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- 208000006561 Cluster Headache Diseases 0.000 claims 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 claims 1
- 208000019505 Deglutition disease Diseases 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 1
- 208000001613 Gambling Diseases 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 208000016604 Lyme disease Diseases 0.000 claims 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- 208000027626 Neurocognitive disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 229940072107 ascorbate Drugs 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- 208000025748 atypical depressive disease Diseases 0.000 claims 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims 1
- 229940077388 benzenesulfonate Drugs 0.000 claims 1
- 150000008107 benzenesulfonic acids Chemical class 0.000 claims 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 1
- 150000001860 citric acid derivatives Chemical class 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 238000000113 differential scanning calorimetry Methods 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 208000024732 dysthymic disease Diseases 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 230000009477 glass transition Effects 0.000 claims 1
- 229940097042 glucuronate Drugs 0.000 claims 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical class OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 229940049920 malate Drugs 0.000 claims 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 1
- 201000003995 melancholia Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 208000015896 paraphilia disease Diseases 0.000 claims 1
- 208000012198 paraphilic disease Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 230000001337 psychedelic effect Effects 0.000 claims 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims 1
- 229960001860 salicylate Drugs 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- 229940095064 tartrate Drugs 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163162749P | 2021-03-18 | 2021-03-18 | |
| US63/162,749 | 2021-03-18 | ||
| US202163276117P | 2021-11-05 | 2021-11-05 | |
| US63/276,117 | 2021-11-05 | ||
| PCT/EP2022/056991 WO2022195011A1 (en) | 2021-03-18 | 2022-03-17 | Psilocybin analogs, salts, compositions, and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024511597A JP2024511597A (ja) | 2024-03-14 |
| JP2024511597A5 JP2024511597A5 (https=) | 2024-11-07 |
| JPWO2022195011A5 true JPWO2022195011A5 (https=) | 2024-11-07 |
Family
ID=87560439
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023556906A Pending JP2024511597A (ja) | 2021-03-18 | 2022-03-17 | シロシビンの類似体、塩、組成物、及び使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240174607A1 (https=) |
| EP (1) | EP4308548A1 (https=) |
| JP (1) | JP2024511597A (https=) |
| KR (1) | KR20230158511A (https=) |
| AU (1) | AU2022239825B2 (https=) |
| BR (1) | BR112023018894A2 (https=) |
| CA (1) | CA3212563A1 (https=) |
| CO (1) | CO2023013714A2 (https=) |
| IL (1) | IL305457A (https=) |
| MX (1) | MX2023010843A (https=) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12022551981A1 (en) * | 2020-02-04 | 2023-10-16 | Mindset Pharma Inc | Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders |
-
2022
- 2022-03-17 JP JP2023556906A patent/JP2024511597A/ja active Pending
- 2022-03-17 IL IL305457A patent/IL305457A/en unknown
- 2022-03-17 MX MX2023010843A patent/MX2023010843A/es unknown
- 2022-03-17 BR BR112023018894A patent/BR112023018894A2/pt unknown
- 2022-03-17 AU AU2022239825A patent/AU2022239825B2/en active Active
- 2022-03-17 KR KR1020237032581A patent/KR20230158511A/ko active Pending
- 2022-03-17 CA CA3212563A patent/CA3212563A1/en active Pending
- 2022-03-17 US US18/547,100 patent/US20240174607A1/en active Pending
- 2022-03-17 EP EP22716857.2A patent/EP4308548A1/en active Pending
-
2023
- 2023-10-18 CO CONC2023/0013714A patent/CO2023013714A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI228116B (en) | Monoamine reuptake inhibitors for treatment of CNS disorders | |
| JP5693814B2 (ja) | 新規のヒスタミンｈ３−受容体リガンドおよびそれらの治療的応用 | |
| JP4181622B2 (ja) | 新規化合物 | |
| CN1678610A (zh) | 奎宁环酰胺衍生物 | |
| JP2015063529A (ja) | アルホルモテロールの合成方法 | |
| JPWO2023078604A5 (https=) | ||
| JP5739415B2 (ja) | （Ｓ）−７−（［１，２，４］トリアゾロ［１，５−ａ］ピリジン−６−イル）−４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロイソキノリンの結晶形態およびその使用 | |
| TW201002682A (en) | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine | |
| WO2003101964A1 (en) | Piperidine derivative, process for producing the same, and use | |
| CN1166622C (zh) | 作为选择性多巴胺d3配体的2-氨基-1,2-二氢化茚 | |
| TW201008937A (en) | Alkylthiazole carbamate derivatives, their preparation and their application in therapy | |
| TW200948784A (en) | Iminopyridine derivatives and use thereof | |
| JP5764553B2 (ja) | ７−（［１，２，４］トリアゾロ［１，５−ａ］ピリジン−６−イル）−４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロイソキノリンおよびその使用 | |
| WO2003024916A1 (en) | Crystals of hydroxynorephedrine derivative | |
| TW200533351A (en) | Compounds for the treatment of diseases | |
| JPH08509212A (ja) | ４−アリールイソインドール鎮痛薬 | |
| JPWO2022195011A5 (https=) | ||
| TW200819455A (en) | Pyrrolizine, indolizine and quinolizine derivatives, their preparation and their therapeutic application | |
| JPWO2023036473A5 (https=) | ||
| CN1452614A (zh) | 芳基哌嗪衍生物及其作为精神药物的用途 | |
| CN101652066A (zh) | 羟甲基醚氢化异吲哚啉速激肽受体拮抗剂 | |
| CN112759544B (zh) | 3-(二甲氨基甲基)哌啶-4-醇衍生物制备方法和药物用途 | |
| RU2194047C2 (ru) | 3-бензилпиперидины, способ их получения и фармацевтическая композиция на их основе | |
| JPWO2022243285A5 (https=) | ||
| CN100422160C (zh) | 新的吗啉衍生物,其制备方法和含有它们的药物组合物 |